WHAT WE DO
Where we operate
We sit at the intersection of science, development and capital. Our work helps de-risk programmes, strengthen execution and support better investment decisions — across UK and GCC geographies.
Development strategy
Senior, hands-on advisory across CMC strategy, analytical development, comparability and lifecycle planning. We help you build the structure your programme needs to move from research to robust development — without losing scientific integrity.
CMC strategy and roadmap
Analytical development and qualification
Comparability strategy across changes
Quality-by-design framing
Lifecycle planning into late-stage
Technical Diligence
Independent assessment of platform technology, manufacturing readiness and execution risk — benchmarked against TRL and MRL frameworks. Built for investors, boards and partners who need a clear, evidence-led read on where a programme stands and where it is most likely to break.
Platform technology assessment
Manufacturing feasibility and scalability (MRL-anchored)
Quality and CMC risk evaluation
Technical due diligence for investment
Operational and execution readiness
METHODOLOGY — TRL & MRL FRAMEWORKS
We assess programmes against established readiness frameworks adapted for advanced therapies:
Technology Readiness Level (TRL 1–9) — platform maturity, scientific validation, system integration.
Manufacturing Readiness Level (MRL 1–10) — process, supply chain, quality systems, scalability.
Clinical translatability — how readiness in the lab translates into a manufacturable, regulatable, fundable programme.
This gives founders, investors and boards a fast, transparent way to compare programmes — and a shared language across technical, commercial and capital conversations.
Investment Intelligence
Translation of complex technical reality into the language of investment. We support funds, family offices and corporate venture teams making capital decisions in cell therapy, gene therapy and advanced therapeutics.
Execution risk assessment
Scalability and commercialisation readiness
Technical insight that informs valuation
Independent perspective for investment committees
Cross-border insight: UK and GCC
Partnership Advisory& Network Catalysis
We help structure collaborations, licensing pathways and strategic partnerships that hold under technical, commercial and regulatory pressure — and we open access through curated networks, including the MCA ecosystem and partner academic and industry hubs.
Partnership and collaboration design
Strategic introductions through curated networks
MCA ecosystem activation
Founder ↔ investor ↔ institution bridging
UK ↔ GCC Bridge
Cross-border programme advisory
Regulatory translation
Capital landscape navigation (UK and GCC)
Strategic positioning for cross-geography expansion
Cultural and stakeholder advisory
Operating across two strategically important biotech geographies. We translate between regulatory regimes, capital cultures and stakeholder expectations — supporting programmes that need to raise, partner or operate across both markets.
